These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 24743397

  • 1. Tissue-specific dysregulation of 11β-hydroxysteroid dehydrogenase type 1 in overweight/obese women with polycystic ovary syndrome compared with weight-matched controls.
    Gambineri A, Fanelli F, Tomassoni F, Munarini A, Pagotto U, Andrew R, Walker BR, Pasquali R.
    Eur J Endocrinol; 2014 Jul; 171(1):47-57. PubMed ID: 24743397
    [Abstract] [Full Text] [Related]

  • 2. A combination of polymorphisms in HSD11B1 associates with in vivo 11{beta}-HSD1 activity and metabolic syndrome in women with and without polycystic ovary syndrome.
    Gambineri A, Tomassoni F, Munarini A, Stimson RH, Mioni R, Pagotto U, Chapman KE, Andrew R, Mantovani V, Pasquali R, Walker BR.
    Eur J Endocrinol; 2011 Aug; 165(2):283-92. PubMed ID: 21622477
    [Abstract] [Full Text] [Related]

  • 3. Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates.
    Tsilchorozidou T, Honour JW, Conway GS.
    J Clin Endocrinol Metab; 2003 Dec; 88(12):5907-13. PubMed ID: 14671189
    [Abstract] [Full Text] [Related]

  • 4. Expression of 11beta-hydroxysteroid dehydrogenase 1 and 2 in subcutaneous adipose tissue of lean and obese women with and without polycystic ovary syndrome.
    Svendsen PF, Madsbad S, Nilas L, Paulsen SK, Pedersen SB.
    Int J Obes (Lond); 2009 Nov; 33(11):1249-56. PubMed ID: 19704410
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A study of the hexose-6-phosphate dehydrogenase gene R453Q and 11beta-hydroxysteroid dehydrogenase type 1 gene 83557insA polymorphisms in the polycystic ovary syndrome.
    San Millán JL, Botella-Carretero JI, Alvarez-Blasco F, Luque-Ramírez M, Sancho J, Moghetti P, Escobar-Morreale HF.
    J Clin Endocrinol Metab; 2005 Jul; 90(7):4157-62. PubMed ID: 15827106
    [Abstract] [Full Text] [Related]

  • 8. Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity.
    Rask E, Walker BR, Söderberg S, Livingstone DE, Eliasson M, Johnson O, Andrew R, Olsson T.
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3330-6. PubMed ID: 12107245
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Increased 5 alpha-reductase activity and adrenocortical drive in women with polycystic ovary syndrome.
    Vassiliadi DA, Barber TM, Hughes BA, McCarthy MI, Wass JA, Franks S, Nightingale P, Tomlinson JW, Arlt W, Stewart PM.
    J Clin Endocrinol Metab; 2009 Sep; 94(9):3558-66. PubMed ID: 19567518
    [Abstract] [Full Text] [Related]

  • 12. Body fat distribution and cortisol metabolism in healthy men: enhanced 5beta-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver.
    Westerbacka J, Yki-Järvinen H, Vehkavaara S, Häkkinen AM, Andrew R, Wake DJ, Seckl JR, Walker BR.
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4924-31. PubMed ID: 14557475
    [Abstract] [Full Text] [Related]

  • 13. Increased clearance of cortisol by 5beta-reductase in a subgroup of women with adrenal hyperandrogenism in polycystic ovary syndrome.
    Gambineri A, Forlani G, Munarini A, Tomassoni F, Cognigni GE, Ciampaglia W, Pagotto U, Walker BR, Pasquali R.
    J Endocrinol Invest; 2009 Mar; 32(3):210-8. PubMed ID: 19542736
    [Abstract] [Full Text] [Related]

  • 14. Increased whole-body and sustained liver cortisol regeneration by 11beta-hydroxysteroid dehydrogenase type 1 in obese men with type 2 diabetes provides a target for enzyme inhibition.
    Stimson RH, Andrew R, McAvoy NC, Tripathi D, Hayes PC, Walker BR.
    Diabetes; 2011 Mar; 60(3):720-5. PubMed ID: 21266326
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Lack of regulation of 11beta-hydroxysteroid dehydrogenase type 1 during short-term manipulation of GH in patients with hypopituitarism.
    Sigurjonsdottir HA, Andrew R, Stimson RH, Johannsson G, Walker BR.
    Eur J Endocrinol; 2009 Sep; 161(3):375-80. PubMed ID: 19549748
    [Abstract] [Full Text] [Related]

  • 17. Addressing the role of 11β-hydroxysteroid dehydrogenase type 1 in the development of polycystic ovary syndrome and the putative therapeutic effects of its selective inhibition in a preclinical model.
    Li X, Hu S, Zhu Q, Yao G, Yao J, Li J, Wang Y, Ding Y, Qi J, Xu R, Zhao H, Zhu Z, Du Y, Sun K, Sun Y.
    Metabolism; 2021 Jun; 119():154749. PubMed ID: 33722534
    [Abstract] [Full Text] [Related]

  • 18. Endogenous inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 do not explain abnormal cortisol metabolism in polycystic ovary syndrome.
    Walker BR, Rodin A, Taylor NF, Clayton RN.
    Clin Endocrinol (Oxf); 2000 Jan; 52(1):77-80. PubMed ID: 10651756
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The expression of 11β-HSDs, GR, and H6PDH in subcutaneous adipose tissue from polycystic ovary syndrome subjects.
    Li S, Tao T, Wang L, Mao X, Zheng J, Zhao A, Liu W.
    Horm Metab Res; 2013 Oct; 45(11):802-7. PubMed ID: 23979790
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.